© 2023 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2023 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Hematology/oncology expert, John P. Leonard, MD, describes the rationale for treating an elderly patient with relapsed/refractory follicular lymphoma with a PI3K inhibitor in the third-line setting.
March 17th 2021
Prior to discussing treatment options for a 71-year-old woman with relapsed/refractory follicular lymphoma, John P. Leonard, MD, of Weill Cornell Medicine and NewYork-Presbyterian Hospital, sets the stage with an overview of the patient’s case.
Important considerations when diagnosing follicular lymphoma, including the rationale for assessing patients’ FLIPI score and looking for any signs of histologic transformation.
Frontline treatment options available to treat newly diagnosed follicular lymphoma, based on a patient’s presentation, and recommendations for offering maintenance therapy following first-line treatment.
Recommendations for appropriately assessing patients with follicular lymphoma with disease progression after frontline treatment and options to consider as second-line therapy.
Treatment options available for patients with relapsed/refractory follicular lymphoma in later-line settings and factors that impact the selection of a PI3K inhibitor over other types of therapies.
John P. Leonard, MD, of Weill Cornell Medicine and NewYork-Presbyterian Hospital, comments on the safety and efficacy data for PI3K inhibitors for relapsed/refractory follicular lymphoma treatment and shares advice on best practices for monitoring patients on therapy and managing any treatment-related adverse events.
Dr John P. Leonard highlights ongoing clinical trials and therapies of interest in the follicular lymphoma pipeline and explains how progress in the field will help address ongoing treatment challenges.